A group of doctors inspired by Memorial Sloan Kettering’s decision not to carry a new colorectal cancer drug (Zaltrap®) due to its cost banded together in hopes of persuading some leading pharmaceutical companies to bring prices down.
A group of more than 100 influential cancer specialists, inspired by Memorial Sloan Kettering’s decision not to carry a new colorectal cancer drug due to its cost, have banded together in hopes of persuading some leading pharmaceutical companies to bring prices down.
Epidemiologist Helena Furberg commented on a study that found that men who are overweight are more likely to have precancerous lesions detected in a benign prostate biopsy and are at a greater risk for subsequently developing prostate cancer.
Interventional radiologist Constantinos Sofocleous discussed a study he led that found that irreversible electroporation, a technique that sends electrical pulses via tiny needles directly to tumors, successfully destroys cancer cells without harming nearby healthy cells.
Gynecologist and geneticist Noah Kauff commented on a study that found that women diagnosed with uterine cancer may have a higher risk of developing colon cancer later in life. He said the increased risk could be due to women with a hereditary condition known as Lynch syndrome.
Visible Ink founder Judith Kelman discussed the Memorial Sloan Kettering program she runs that connects patients with experienced writers, editors, and teachers to help them tell their stories in writing. A Memorial Sloan Kettering patient and program participant was also interviewed.
Endocrinologist James Fagin spoke about a study he led that found that an investigational drug may help some patients with thyroid cancer who are unable to absorb radioactive iodine, the most effective therapy for the disease.